A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics and Safety of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) and to Characterize the Pharmacokinetics of Trametinib's Metabolite M5 in Female Subjects With Solid Tumors

Trial Profile

A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics and Safety of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) and to Characterize the Pharmacokinetics of Trametinib's Metabolite M5 in Female Subjects With Solid Tumors

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Trametinib (Primary) ; Ethinylestradiol/norethisterone
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 25 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
    • 11 Sep 2015 Planned initiation date changed from 1 Sep 2015 to 1 Feb 2016 as per ClinicalTrials.gov record.
    • 26 Mar 2015 Planned initiation date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top